Varied albuterol dose response — Competitive Intelligence Brief

Varied albuterol dose response (Varied albuterol dose response) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-2 adrenergic agonist (short-acting bronchodilator). Area: Respiratory/Pulmonology.

marketed Beta-2 adrenergic agonist (short-acting bronchodilator) Beta-2 adrenergic receptor (ADRB2) Respiratory/Pulmonology Small molecule

Target snapshot

Varied albuterol dose response (Varied albuterol dose response) — Oregon Health and Science University. Albuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Varied albuterol dose response TARGET	Varied albuterol dose response	Oregon Health and Science University	marketed	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor (ADRB2)
Albuterol eMDPI DS	Albuterol eMDPI DS	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor
terbutaline sulfate (Bricasol)	terbutaline sulfate (Bricasol)	AstraZeneca	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor (ADRB2)
Albuterol MDPI	Albuterol MDPI	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor (ADRB2)
racemic albuterol MDI	racemic albuterol MDI	Sumitomo Pharma America, Inc.	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor
Ventolin® MDI	Ventolin® MDI	Taiwan Otsuka Pharm. Co., Ltd	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor
albuterol inhalation powder	albuterol inhalation powder	Amphastar Pharmaceuticals, Inc.	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-2 adrenergic agonist (short-acting bronchodilator) class)

1. Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
2. Amphastar Pharmaceuticals, Inc. · 1 drug in this class
3. AstraZeneca · 1 drug in this class
4. Oregon Health and Science University · 1 drug in this class
5. Sumitomo Pharma America, Inc. · 1 drug in this class
6. Taiwan Otsuka Pharm. Co., Ltd · 1 drug in this class